| Elizabeth Manetta, MD | |
|
2873 S Eagle Rd, Newtown, PA 18940-1590 | |
| (267) 364-6477 | |
| Not Available |
| Full Name | Elizabeth Manetta |
|---|---|
| Gender | Female |
| Speciality | Sports Medicine |
| Experience | 7 Years |
| Location | 2873 S Eagle Rd, Newtown, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518496611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD474020 (Pennsylvania) | Secondary |
| 207QS0010X | Family Medicine - Sports Medicine | MD474020 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Medical Group | 0941103683 | 463 |
News Archive
Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.
Purposefully and repeatedly exposing children to secondhand smoke — a known human carcinogen — is child abuse, according to an opinion piece written by Adam Goldstein, MD, MPH, a professor in the Department of Family Medicine at the University of North Carolina School of Medicine.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.
The ongoing COVID-19 pandemic has baffled researchers with its propensity to cause symptoms of largely unpredictable severity in the affected individuals. An exciting new study reports on the potential predictive value of platelet size in this situation. COVID-19 patients with severe disease often develop clots in vital organs, which leads to further complications. It is known that platelet size is a good indicator of activation.
› Verified 8 days ago
| Entity Name | Lancaster General Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952392383 PECOS PAC ID: 0941103683 Enrollment ID: O20040309000916 |
News Archive
Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.
Purposefully and repeatedly exposing children to secondhand smoke — a known human carcinogen — is child abuse, according to an opinion piece written by Adam Goldstein, MD, MPH, a professor in the Department of Family Medicine at the University of North Carolina School of Medicine.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.
The ongoing COVID-19 pandemic has baffled researchers with its propensity to cause symptoms of largely unpredictable severity in the affected individuals. An exciting new study reports on the potential predictive value of platelet size in this situation. COVID-19 patients with severe disease often develop clots in vital organs, which leads to further complications. It is known that platelet size is a good indicator of activation.
› Verified 8 days ago
| Entity Name | Tower Health Urgent Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194293647 PECOS PAC ID: 2668716069 Enrollment ID: O20181211002273 |
News Archive
Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.
Purposefully and repeatedly exposing children to secondhand smoke — a known human carcinogen — is child abuse, according to an opinion piece written by Adam Goldstein, MD, MPH, a professor in the Department of Family Medicine at the University of North Carolina School of Medicine.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.
The ongoing COVID-19 pandemic has baffled researchers with its propensity to cause symptoms of largely unpredictable severity in the affected individuals. An exciting new study reports on the potential predictive value of platelet size in this situation. COVID-19 patients with severe disease often develop clots in vital organs, which leads to further complications. It is known that platelet size is a good indicator of activation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Manetta, MD Po Box 13579, Reading, PA 19612-3579 Ph: (484) 628-1324 | Elizabeth Manetta, MD 2873 S Eagle Rd, Newtown, PA 18940-1590 Ph: (267) 364-6477 |
News Archive
Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.
Purposefully and repeatedly exposing children to secondhand smoke — a known human carcinogen — is child abuse, according to an opinion piece written by Adam Goldstein, MD, MPH, a professor in the Department of Family Medicine at the University of North Carolina School of Medicine.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.
The ongoing COVID-19 pandemic has baffled researchers with its propensity to cause symptoms of largely unpredictable severity in the affected individuals. An exciting new study reports on the potential predictive value of platelet size in this situation. COVID-19 patients with severe disease often develop clots in vital organs, which leads to further complications. It is known that platelet size is a good indicator of activation.
› Verified 8 days ago
Dr. Michael B Fischer, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2950 South Eagle Rd., Newtown, PA 18940 Phone: 215-504-9255 Fax: 215-504-9260 | |
Dr. Barbara Mirth-jacobelli, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1382 Newtown Langhorne Rd, Newtown, PA 18940 Phone: 215-968-9110 | |
Joseph Kipp, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Friends Ln, Suite 101, Newtown, PA 18940 Phone: 215-579-1300 Fax: 215-579-0150 | |
John M Lawless Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Friends Ln, Suite 101, Newtown, PA 18940 Phone: 215-579-1300 Fax: 215-579-0150 | |
Jane Flynn-abdalla, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Penns Trl, Newtown, PA 18940 Phone: 215-504-1761 Fax: 215-504-1721 | |
Randi Banner, CRNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1382 Newtown Langhorne Rd, Newtown, PA 18940 Phone: 215-504-6809 Fax: 215-579-0266 | |
Dr. Barbara M Saracino, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 638 Newtown Yardley Rd Ste 2e, Newtown, PA 18940 Phone: 215-968-1616 Fax: 215-860-1976 |